Sign up to save your podcasts
Or
Share No pain, no gain: Ozempic’s quest for market share
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
No pain, no gain: Ozempic’s quest for market share
The shock success of GLP-1 treatments for obesity carries massive implications for wealthy societies and manufacturers Novo Nordisk and Eli Lilly alike. In this week’s Viewsroom podcast, Breakingviews columnists discuss how this would-be jackpot has companies running to keep up.
Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By Reuters
4.2
4444 ratings
The shock success of GLP-1 treatments for obesity carries massive implications for wealthy societies and manufacturers Novo Nordisk and Eli Lilly alike. In this week’s Viewsroom podcast, Breakingviews columnists discuss how this would-be jackpot has companies running to keep up.
Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.
Learn more about your ad choices. Visit megaphone.fm/adchoices
More shows like Viewsroom
View all
WSJ Tech News Briefing
1,636 Listeners
Economist Podcasts
4,184 Listeners
WSJ What’s News
4,357 Listeners
Bloomberg Businessweek
419 Listeners
Trumponomics
351 Listeners
The Big View
25 Listeners
WSJ Minute Briefing
681 Listeners
The Intelligence from The Economist
2,533 Listeners
The Journal.
6,017 Listeners
The World in Brief from The Economist
1,079 Listeners
AP Newswatch: Top Stories from the Associated Press
52 Listeners
The Big Take
156 Listeners
The State of It
85 Listeners
Reuters World News
264 Listeners
Reuters Econ World
28 Listeners